-
Clinical testing service
- Tumor personalized liquid biopsy Lung cancer detection Gastric and colorectal cancer treatment target detection Female gynecological oncology Pan-cancerous solid tumor (multi-cancer) Chemotherapy guidance Hereditary tumor detection
- Tumor personalized clinical testing Lung cancer detection Gastric and colorectal cancer treatment target detection Female gynecological oncology Immunity therapy Pan-cancerous solid tumor (multi-cancer) Chemotherapy guidance Hereditary tumor detection
APP download
Tel: +86-571-89360709 E-mail: service@repugene.com
Address: 21-23, Health Valley, No. 1500, Wenyi West Road, Yuhang District, Hangzhou, Zhejiang, China
Copyright: Hangzhou Repugene Technology Co., Ltd. Powered by www.300.cn
浙ICP备16003170号
Address: 21-23, Health Valley, No. 1500, Wenyi West Road, Yuhang District, Hangzhou, Zhejiang, China
Copyright: Hangzhou Repugene Technology Co., Ltd. Powered by www.300.cn
浙ICP备16003170号
Hangzhou Repugene Technology Co., Ltd. is a high-tech advanced biomedical research and development enterprise with the team of Dr. Haigui.
core team
Chief Medical Consultant Dr. Mao Li
Release time：
2019/01/19 17:18
Page view
[Abstract]:
Dr. Mao Li, Senior Vice President and Chief Medical Officer of Beida Pharmaceutical;
a tenured professor at the University of Texas Anderson Cancer Center;
Professor of Changjiang Scholars, School of Medicine, Shanghai Jiaotong University; expert of the National “Thousand Talents Program”;
Chief medical consultant
Dr. Mao Li, Senior Vice President and Chief Medical Officer of Beida Pharmaceutical;
a tenured professor at the University of Texas Anderson Cancer Center;
Professor of Changjiang Scholars, School of Medicine, Shanghai Jiaotong University; expert of the National “Thousand Talents Program”;
He was the head of the Department of Oncology and Diagnostics at the University of Maryland, and the vice president of the Johnson & Johnson Group and director of the Lung Cancer Center.
He has made pioneering contributions in the fields of tumor molecular biology, early molecular diagnosis and high-risk prediction, prevention and precision treatment of lung cancer and oral cancer, and has been in Science, New England Journal of Medicine, Nature Medicine, and Nature. More than 200 papers have been published in SCI magazines such as Genetics, with a total citation of more than 24,000.
Previous article:
Chief Clinical Medicine Consultant Professor Wang Yi